A live-attenuated Ebola vaccine has demonstrated promising results in a Phase I randomized controlled trial assessing safety and immunogenicity, according to a Canadian study.
Browsing: Emerging Disease > Ebola
Author, Mark Woolhouse, discusses recent efforts to identify pathogens with pandemic potential and his own work on emerging viruses.
Researchers examining post-Ebola syndrome have discovered ocular consequences, including a disease-associated retinal scar.
John-Arne Røttingen discusses his role as founding CEO of the Coalition for Epidemic Preparedness Innovations (CEPI) and his thoughts on the importance of developing new vaccines for emerging threats.
International collaborative research has analyzed Ebola virus genomes from the 2013–2016 outbreak, uncovering the role of factors such as language and distance between cities.
Although understanding of Ebola virus pathogenesis has rapidly increased recently, many questions relating to the role of the vascular system remain unanswered. The authors here discuss how Ebola virus infection can cause endothelial dysfunction and coagulopathy.
A Phase I clinical trial has demonstrated two investigational Ebola vaccines generate a durable immune response 1 year after vaccination.
In this piece, author Jean-François Etard, summarizes his work on the Postebogui cohort and argues that patients declared free of Ebola virus disease should receive follow-up for at least 18 months after discharge from treatment centers.
Researchers have suggested that disease “superspreaders” may have been responsible for two-thirds of cases in the West Africa Ebola epidemic. Targeting these individuals could lead to better disease control measures in future outbreaks.